Bank of New Hampshire Sells 115 Shares of Johnson & Johnson (NYSE:JNJ)

Bank of New Hampshire lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.8% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 14,639 shares of the company’s stock after selling 115 shares during the quarter. Bank of New Hampshire’s holdings in Johnson & Johnson were worth $2,428,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of JNJ. WealthTrak Capital Management LLC purchased a new stake in Johnson & Johnson in the 4th quarter worth about $26,000. Mountain Hill Investment Partners Corp. purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $29,000. Bay Harbor Wealth Management LLC bought a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $32,000. Conquis Financial LLC purchased a new position in Johnson & Johnson during the 4th quarter valued at $33,000. Finally, Bernard Wealth Management Corp. bought a new position in Johnson & Johnson in the 4th quarter valued at $36,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Performance

JNJ stock opened at $155.02 on Friday. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The firm has a market cap of $372.99 billion, a price-to-earnings ratio of 23.31, a PEG ratio of 2.56 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The firm has a 50-day simple moving average of $153.59 and a two-hundred day simple moving average of $153.68.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. On average, equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 3.35%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date is Tuesday, May 27th. Johnson & Johnson’s payout ratio is 57.84%.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Morgan Stanley lifted their target price on Johnson & Johnson from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 16th. Leerink Partners downgraded shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Bank of America lowered their price objective on shares of Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday, April 10th. Benchmark raised shares of Johnson & Johnson to a “strong-buy” rating in a research report on Thursday, April 24th. Finally, Guggenheim reiterated a “neutral” rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Eleven equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.